Are You Caring for Patients with Heart Disease?

Heart disease remains the nation’s leading cause of death1

About 655,000 Americans die from heart disease each year – an estimated 1 in every 4 deaths – with coronary artery disease (CAD) being the most common type of heart disease2. Epidemiological studies have Identified CAD as a major contributor to heart failure burden, with angiographic evidence of CAD being a significant marker for a worse heart failure prognosis, increasing mortality risk by 250%.2

  • Estimated prevalence of CAD in patients with heart failure is 50-65%3
  • CAD represents a potentially treatable or reversible cause of heart failure3
  • Only 17.5% of patients with CAD who were hospitalized for new on-set heart failure were tested for ischemic coronary artery disease3
  • Upfront ischemic testing can lead to lower resource utilization in terms of ED visits and rehospitalization for complications of CAD and heart failure3

A Growing Population Appropriate for PCI

Is Your Patient a Candidate for Protected PCI?

Use this tool to determine if a patient may be appropriate to receive a Protected PCI procedure.

 

Why is Protected PCI Important?

The use of the Impella heart pump during a PCI allows blood pressure to be maintained during the procedure, allowing the physician to perform a more complete and optimized procedure. Protected PCI with Impella heart pumps has been proven to improve quality of life for these patients and help them return home faster.2,3

 

How Do Impella® Heart Pumps Work?

Impella, the world’s smallest heart pump, allows the heart to rest by protecting the patient hemodynamically during a high-risk procedure. Impella heart pumps provide direct left ventricular unloading by pulling blood from the left ventricle and expelling it into the aorta, increasing total cardiac output/arterial pressure and reducing myocardial oxygen consumption. For patients in right heart failure, the right-sided Impella heart pump delivers blood from the inferior vena cava to the pulmonary artery.

Ongoing and Upcoming Clinical Trials

Investigating whether the extent of complete revascularization is associated with the degree of LVEF improvement.

Learn More

Ongoing trial to compare complete revascularization PCI with Impella to complete revascularization PCI without any planned hemodynamic support.

Learn More

Ongoing PMA study of Impella 2.5 and Impella CP demonstrating reduction in MACCE at 90 days with Impella-supported Protected PCI compared to PROTECT II.

Learn More

Find a Hospital Near You

Find a hospital near you that offers Protected PCI with Impella.

Contact Us

Click here to reach out to learn more from Abiomed’s therapy awareness team to learn more about Impella benefits and patient identification. 

References

  1. CDC: About Heart Disease

  2. Velagaleti, R., et al., (2007). Cardio Clin, 25(4) 487-495.

  3. Doshi D, et al., (2016). J Am Coll Cardiol, 68(5), 450-458.

 

NPS-1478